Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Concordia Healthcare Corp. T.CXR.R

TSX:CXR.R - Post Discussion

View:
Post by ryehigh2014 on Oct 18, 2016 8:36pm

REALIZED

None of you a$$hole retail shorts can afford a BBG terminal lol. Marc can. so can his buddies. 

Don't be fooled. Squeeze is coming after the mess of Q3 (if any mess). Please mark this post. 

Note: I only say mess because Im eager to see what impact GBPUSD from 1.31 to 1.21 has had.
Comment by cg16 on Oct 18, 2016 8:57pm
Rye, I don't think we will see the effect of the weak pound on Q3 since it was over at end of September and the pound dove just after that basically. Pound was above 1.3 most of Q3.. Q3 and Q4 are supposedly stronger quarters for Pharma. Interesting see if that holds true with CXR. 
Comment by ryehigh2014 on Oct 18, 2016 9:03pm
Like I said. CXRX is a rollup with a proven portfolio but also slowly declining. You need to accept the company for what it is and model it as such. Anyways I agree with you on the rate. BUT markets are forward pricing right? So if a large chunk of revenue is in sterling and GBPUSD is rallying this is overall positive. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities